Cargando…

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

OBJECTIVES: This phase II trial evaluated the efficacy and safety of an interleukin (IL) 6 monoclonal antibody for systemic lupus erythematosus (SLE). METHODS: Patients with active disease were randomised to placebo or PF-04236921 10 mg, 50 mg or 200 mg, subcutaneously, every 8 weeks with stable bac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallace, Daniel J, Strand, Vibeke, Merrill, Joan T, Popa, Serghei, Spindler, Alberto J, Eimon, Alicia, Petri, Michelle, Smolen, Josef S, Wajdula, Joseph, Christensen, Jared, Li, Cheryl, Diehl, Annette, Vincent, Michael S, Beebe, Jean, Healey, Paul, Sridharan, Sudhakar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446001/ https://www.ncbi.nlm.nih.gov/pubmed/27672124 http://dx.doi.org/10.1136/annrheumdis-2016-209668

Ejemplares similares

Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE) †
por: Ponticelli, Claudio, et al.
Publicado: (2010)

Therapy of systemic lupus erythematosus: a look into the future
por: Smolen, Josef S
Publicado: (2002)

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
por: Bangert, Elvira, et al.
Publicado: (2019)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

The role of tumor necrosis factor-alpha in systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2008)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
por: Furie, Richard, et al.
Publicado: (2014)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
por: Wallace, Daniel J, et al.
Publicado: (2014)

Unmet medical needs in systemic lupus erythematosus
por: Lateef, Aisha, et al.
Publicado: (2012)

Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus
por: Bolton, Chrissy, et al.
Publicado: (2020)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
por: Strand, Vibeke, et al.
Publicado: (2020)

Long‐Term Impact of Belimumab on Health‐Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment
por: Strand, Vibeke, et al.
Publicado: (2019)

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
por: Strand, Vibeke, et al.
Publicado: (2014)

Advances in drug therapy for systemic lupus erythematosus
por: Wallace, Daniel J
Publicado: (2010)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus
por: Petri, Michelle A, et al.
Publicado: (2020)

Nonlymphoma hematological malignancies in systemic lupus erythematosus
por: Lu, M, et al.
Publicado: (2012)

Lung cancer in systemic lupus erythematosus
por: Kale, M, et al.
Publicado: (2012)

Phenotypic and functional deficiencies of monocyte derived dendritic cells in systemic lupus erythematosus patients
por: Scheinecker, C, et al.
Publicado: (2004)

Acquired Von Willebrand's Syndrome in Systemic Lupus Erythematosus
por: Taveras Alam, Sara, et al.
Publicado: (2014)

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
por: Khamashta, Munther, et al.
Publicado: (2016)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Kikuchi–Fujimoto disease and systemic lupus erythematosus
por: Baenas, Diego F, et al.
Publicado: (2016)

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
por: Wallace, Daniel J., et al.
Publicado: (2019)

Lupus Erythematosus
por: Gardiner, Frederick
Publicado: (1923)

Lupus Erythematosus
por: Ravogli, A.
Publicado: (1887)

SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2003)

Quantitative and qualitative analysis of CD4(+)CD25(+ )regulatory T cells in systemic lupus erythematosus patients
por: Bonelli, M, et al.
Publicado: (2005)

Linear cutaneous lupus erythematosus/discoid lupus erythematosus in an adult
por: Mao, Qiu-Xia, et al.
Publicado: (2017)

Therapy Side Effects in Systemic Lupus Erythematosus
por: POPA, R., et al.
Publicado: (2018)

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
por: Kim, Mimi, et al.
Publicado: (2018)

Systemic lupus Erythematosus and geomagnetic disturbances: a time series analysis
por: Stojan, George, et al.
Publicado: (2021)

Clinical and immunological effects of anti-TNF therapy in systemic lupus erythematosus (SLE)
por: Aringer, M, et al.
Publicado: (2003)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
por: Cevey, Maria, et al.
Publicado: (2019)

Pauci-immune Glomerulonephritis in Systemic Lupus Erythematosus (SLE)
por: Liebowitz, Jason, et al.
Publicado: (2018)

Autoreactive T cells to histone H1 and core histones in patients with systemic lupus erythematosus
por: Stummvoll, GH, et al.
Publicado: (2005)

Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
por: Specchia, Maria Lucia, et al.
Publicado: (2014)

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
por: Narwal, Rajesh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_71up5hl04vdo3ikp46cc5vj9ef